Loading
The largest screening trial ever run for ovarian cancer found earlier detection but no reduction in deaths, so there is still no recommended screening.
Over 16 years of follow-up, multimodal screening shifted stage at diagnosis but did not reduce ovarian and tubal cancer deaths by a statistically significant margin (Lancet 2021). It is the central reason no guideline recommends population screening and why effort has moved to risk-reducing salpingectomy and multi-cancer blood tests.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
202,638 enrolled.
relative reduction, not significant
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Ovarian and tubal cancer mortality reduction (multimodal vs none)primary | Multimodal screening | - | 4% | - | - | link |
Shares Serum tumour markers: proper use and misuse, Ultrasound, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares Surrogate endpoint, Surrogate endpoint validation: which stand-ins have earned trust, Why trials fail: underpowered, wrong endpoint, control arm drift, subgroup fishing, crossover.
Shares CA-125, Ovarian cancer.
Shares CA-125, Serum tumour markers: proper use and misuse, Ovarian cancer.
Shares Stage shift, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares Stage shift, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares Stage shift, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares Surrogate endpoint, Surrogate endpoint validation: which stand-ins have earned trust, Why trials fail: underpowered, wrong endpoint, control arm drift, subgroup fishing, crossover.